Selux Diagnostics is pioneering advancements in antibiotic susceptibility testing (AST) through its innovative Next Generation Phenotyping (NGP) System. This system addresses the urgent need for rapid and accurate AST, which has not seen significant innovation in over two decades. The Selux Analyzer, the core of the NGP System, is designed to deliver results in an average of 5.5 hours, utilizing a unique 86-panel capacity that allows for high throughput and random access. This capability enables simultaneous testing of multiple samples, significantly enhancing the speed and accuracy of results. The system employs proprietary assays, including the Viability Assay and Surface Area Assay, which provide a more precise analysis of bacterial health and resistance mechanisms than traditional methods.

The Selux NGP System is committed to updating breakpoints to ensure patient safety and effective antibiotic stewardship. By utilizing broad dilutions, the system facilitates easy updates to breakpoints, addressing the critical issue of outdated standards that can jeopardize patient care. The combination of rapid results, comprehensive testing against a wide range of antibiotics, and a focus on accurate measurement of bacterial response positions Selux Diagnostics as a leader in the fight against antimicrobial resistance. This innovative approach not only aims to improve patient outcomes but also seeks to combat the growing threat of superbugs, which are projected to become a leading cause of death in the coming decades.

United States

Infectious Diseases

56 Roland St. Suite 206, Charlestown, MA 02129

Selux Diagnostics

Company Details